



TSX-V: QPT

A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life

Quest has 6 independent business units under its umbrella

- Each brings unique technologies to enhance shareholder value
- Operating under their own management, clinical team and Board

Major Focus on the treatment of cancer

- OncoQuest - Antibody Based Combination Immunotherapy
- AmrutBio - Targeted Cancer Therapy
- OncoVent - China Joint Venture for Immunotherapy

Other individual business units bring revenue with development, distribution and sales of consumer health products

- Madenco Biosciences – Cosmetics and consumer health products
- Bioceltran – Transdermal Delivery (PTD) Technology and Photodynamic Therapy Technology
- Natural Rf Life Sciences – First product Allergy Rf, science based clinically proven natural health products

TSX-Venture Exchange Listed	Symbol: QPT
Year Founded	1996
Year Listed	1999
Share Capital	\$35.6 M
Licensing Fees to Date	\$ 9.6 M
Shares Outstanding	167 M
Warrants and Options Outstanding	20 M
Shareholder Base	South Korea 42% Canada 25% China 17% US 3% Europe 7 % Insiders 6%

Recent News

Jul 19, 2017

Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors

May 14, 2017

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 09, 2017

OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

May 04, 2017

Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief

Dec 07, 2016







OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

Nov 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

Nov 02, 2016

OncoVent Initiates Clinical Development Program for Anti-MUC1 MAB AR20.5 for Treatment of Pancreatic Cancer

	Business Units	Highlights	Quest Ownership Info
Cancer Therapies	 OncoQuest INC.	Three different combinatorial immunotherapy clinical trials are underway for the treatment of ovarian cancer with oregovomab Her2/neu IgE preclinical development for metastatic breast cancer	50.1%
	 OncoVent 昂納生物科技	Anti-MUC1 MAB AR 20.5 for pancreatic cancer development in China	11 %
	 AmrutBio	Novel targeted therapy (truncated MUC-16) development for cancer in collaboration with UNMC	100 %
Consumer Products	 MADENCO Biosciences Inc.	Global commercialization of cosmetic and dermatology products based on proprietary transdermal delivery technologies (www.belluskin.com)	82 %
	 BIOCELTRAN 바이오셀트란	New drug development based on Photodynamic Therapy or Protein Transduction Technology	20 %
	 natural Rf LIFE SCIENCES	Allergy Rf - The Only Clinically Proven Natural Health Product for Seasonal and Environmental Allergy In Canada	32 %

Why Quest PharmaTech?

- Unique Business Model with Six Strategic Business Units
- Multiple Products in the Clinic
- Diversified Product Pipeline
- Well Financed to meet Milestones
- Creating shareholder value with unique therapies and technologies
- Potential Revenue Generation with Consumer Products Sales
- Experienced management team
- Global network of collaborators and Investors (US, Korea, Europe and China)
- Extensive patent portfolio
- Considerable scientific and clinical publications in peer reviewed journals



TSX-V: QPT

Quest Scientific Advisory Board Members

Dr. Chris Nicodemus (Chair)
President & CSO, AIT Strategies, US

Dr. Michael A Hollingsworth, Ph.D.
Professor, Eppley Institute, University of Nebraska Medical Center, US

Dr. Eric Shi, Ph.D.
Professor, Nanjing Medical University & Associate Dean, Academy of Clinical & Translational Research, Jiangsu Province

Dr. Ki-Jun Hwang, Ph.D.
Director of Centre for Research in Bioactive Materials, Chonbuk National University, Korea

Dr. Ronald Moore, M.D., Ph.D., FRCSC
Cross Cancer Institute, University of Alberta Hospital, Edmonton, Canada

OFFICERS AND DIRECTORS

Dr. Madi R. Madiyalakan, Ph.D.
CEO and Director

Mr. Lorne Meikle, B.A
Chairman, Director

Dr. Eris Shi, Ph.D.
Director

Mr. J. Mark Lievonon, C.M., FCPA, FCA, BBA, MBA, LLD
Director

Mr. Shawn Lu, CIM, M. Finan.
Director

Mr. Pierre Vermette, C.A.
Chief Financial Officer

CONTACT INFORMATION

Dr. Madi R. Madiyalakan, CEO
(780) 448-1400 ext.204
madi@questpharmatech.com

A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life



- developing next generation of combinatorial immunotherapy products for the treatment of cancer
- Positive interim results from Phase II clinical study of lead product (oregovomab) with excellent safety profile provides path to a product registration trial
- Initiated antibody manufacturing program to support planned registration trial and commercial use.
- Diversified product pipeline covering almost all cancers that kill, and a novel product class that may qualify for breakthrough designation (IgE). Potential optimization in combination with chemotherapy, immuno-stimulants and checkpoint inhibition
- A China based global pharmaceutical company as major investor and development partner, Hepalink USA



- Joint Venture with Shenzhen Hepalink Pharmaceutical Co., Ltd
- Focus on development of combination immunotherapy for the China market
- Initiated anti-MUC1 MAb AR20.5 manufacturing for Phase II study in pancreatic cancer
- Leverage additional resources to accelerate worldwide Antibody Manufacturing and Clinical Development Strategy

AmrutBio

- Novel approach for targeted cancer therapy using a combinatorial approach for optimal efficacy
- Lead product (MAb AR9.6) under development is for a novel target (MUC 16) for cancer therapy discovered at University of Nebraska Medical Center
- Second product (ACP2127) under development is a multi-functional inhibitor combining the effect of CDK and mTOR inhibition



- Focused on commercializing scientifically validated consumer health products through development, licensing and acquisition
- Product categories include cosmetics, natural health products and Rx Pharma
- Products based on proprietary transdermal delivery technology licensed from Bioceltran (SP Technology)
- Global Distribution (ex-Korea)- Rights to Bellus Skin Cosmetics



- Quest owns Photodynamic Therapy Technology and Bioceltran owns Protein Transduction Domain (PTD) Technology
- Quest and Bioceltran are developing skin penetrating active molecules for cosmetic and pharmaceutical use
- Quest has worldwide (excluding South Korea) rights to Bioceltran PTD Technology and Products for certain indications
- Bioceltran has exclusive license to Quest's Photodynamic Therapy Technology



- Development of science based, clinically proven natural health products
- First product approved – Allergy Rf
- Managed by Dr. Jacqueline Shan